-
1
-
-
30144443996
-
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
-
Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265-276.
-
(2006)
Blood
, vol.107
, pp. 265-276
-
-
Morton, L.M.1
Wang, S.S.2
Devesa, S.S.3
-
2
-
-
0037165261
-
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
-
Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
-
(2002)
N Engl J Med
, vol.346
, pp. 235-242
-
-
Coiffier, B.1
Lepage, E.2
Briere, J.3
-
3
-
-
23044503407
-
Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-Cell lymphoma: A study by the groupe d?Etude des Lymphomes de l?Adulte
-
Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-Cell lymphoma: A study by the groupe d?Etude des Lymphomes de l?Adulte. J Clin Oncol 2005;23:4117-4126.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4117-4126
-
-
Feugier, P.1
Van Hoof, A.2
Sebban, C.3
-
4
-
-
77957200763
-
Long-term outcome of patients in the LNH-98.5 trial the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the groupe d?Etudes des Lymphomes de l?Adulte
-
Cuiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: A study by the groupe d?Etudes des Lymphomes de l?Adulte. Blood 2010;116:2040-2045.
-
(2010)
Blood
, vol.116
, pp. 2040-2045
-
-
Cuiffier, B.1
Thieblemont, C.2
Van Den Neste, E.3
-
5
-
-
38549147027
-
Sixversus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD2O + B-Cell lymphomas: A randomised controlled trial (RICOVER-60)
-
Pfreundschuh M, Schubert J, Ziepert M, et al. Sixversus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD2O + B-Cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
-
(2008)
Lancet Oncol
, vol.9
, pp. 105-116
-
-
Pfreundschuh, M.1
Schubert, J.2
Ziepert, M.3
-
6
-
-
0021282245
-
Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly:Increased complications with advancing age
-
Armitage JO, Potter JR Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly:Increased complications with advancing age. JAm Geriatr Soc 1984;32:269-273.
-
(1984)
JAm Geriatr Soc
, vol.32
, pp. 269-273
-
-
Armitage, J.O.1
Potter, J.R.2
-
7
-
-
0022602852
-
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma:The Southwest Oncology Group experience
-
Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma:The Southwest Oncology Group experience. J Clin Oncol 1986;4:295-305.
-
(1986)
J Clin Oncol
, vol.4
, pp. 295-305
-
-
Dixon, D.O.1
Neilan, B.2
Jones, S.E.3
-
8
-
-
0025063109
-
Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables
-
Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer 1990;66:1124-1129.
-
(1990)
Cancer
, vol.66
, pp. 1124-1129
-
-
Epelbaum, R.1
Faraggi, D.2
Ben-Arie, Y.3
-
9
-
-
0025363033
-
Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis
-
Kwak LW, Halpern J, Olshen BA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977.
-
(1990)
J Clin Oncol
, vol.8
, pp. 963-977
-
-
Kwak, L.W.1
Halpern, J.2
Olshen, B.A.3
-
10
-
-
0027495838
-
Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe Detude des Lymphomes de Iadulte)
-
Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin?s lymphoma patients: Application to LNH-87 protocol. The GELA. (Groupe d?Etude des Lymphomes de l?Adulte). Ann Oncol 1993;4:651-656.
-
(1993)
Ann Oncol
, vol.4
, pp. 651-656
-
-
Lepage, E.1
Gisselbrecht, C.2
Haioun, C.3
-
11
-
-
0029095966
-
Randomized phase 11 comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma
-
Meyer RM, Browman GP, Samosh ML, et al. Randomized phase 11 comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin?s lymphoma. J Clin Oncol 1995;13:2386-2393.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2386-2393
-
-
Meyer, R.M.1
Browman, G.P.2
Samosh, M.L.3
-
12
-
-
0029162440
-
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy
-
Sonneveld P, de Ridder M, Van Der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin?s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
-
(1995)
J Clin Oncol
, vol.13
, pp. 2530-2539
-
-
Sonneveld, P.1
De Ridder, M.2
Van Der Lelie, H.3
-
13
-
-
7344231043
-
Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin's lymphoma
-
Central Lymphoma Group
-
Bailey NP, Stuart NS, Bessell EM, et al. Five-year follow-up of a prospective randomised multi-centre trial of weekly chemotherapy (CAPOMEt) versus cyclical chemotherapy (CHOP-Mtx) in the treatment of aggressive non-Hodgkin?s lymphoma. Central Lymphoma Group. Ann Oncol 1998;9:633-638.
-
(1998)
Ann Oncol
, vol.9
, pp. 633-638
-
-
Bailey, N.P.1
Stuart, N.S.2
Bessell, E.M.3
-
14
-
-
0004815869
-
CHOP is the standard regimen in patients > or 70 years of age with intermediate-grade and high-grade non-Hodgkins lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group
-
TirelliU, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients or 70 years of age with intermediate-grade and high-grade non-Hodgkin?s lymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16:27-34.
-
(1998)
J Clin Oncol
, vol.16
, pp. 27-34
-
-
Tirelli, U.1
Errante, D.2
Van Glabbeke, M.3
-
15
-
-
41249092380
-
Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-Cell lymphoma patients treated with CHOP
-
Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-Cell lymphoma patients treated with CHOP. Ann Hematol 2008;87:277-283.
-
(2008)
Ann Hematol
, vol.87
, pp. 277-283
-
-
Bosly, A.1
Bron, D.2
Van Hoof, A.3
-
16
-
-
77955660165
-
Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-Cell lymphoma
-
Hirakawa T, Yamaguchi H, Yokose N, et al. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-Cell lymphoma. Ann Hematol 2010;89:897-904.
-
(2010)
Ann Hematol
, vol.89
, pp. 897-904
-
-
Hirakawa, T.1
Yamaguchi, H.2
Yokose, N.3
-
17
-
-
79955473473
-
Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-Cell lymphoma: A multicentre, single-arm, phase 2 trial
-
Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-Cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-468.
-
(2011)
Lancet Oncol
, vol.12
, pp. 460-468
-
-
Peyrade, F.1
Jardin, F.2
Thieblemont, C.3
-
18
-
-
0023092594
-
A newmethod of classifying prognostic comorbidity in longitudinal studies: Development and validation
-
Charlson ME, Pompei P, Ales XL, et al. A newmethod of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-383.
-
(1987)
J Chronic Dis
, vol.40
, pp. 373-383
-
-
Charlson, M.E.1
Pompei, P.2
Ales, X.L.3
-
19
-
-
0042449063
-
Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
-
Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin?s lymphomas. NCI Sponsored International Working Group. J din Oncol 1999; 17: 1244.
-
(1999)
J Din Oncol
, vol.17
, pp. 1244
-
-
Cheson, B.D.1
Horning, S.J.2
Coiffier, B.3
-
20
-
-
77957371624
-
Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-Cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793). Consideration of age greater than 70 years in an elderly prognostic index (E-1PI)
-
Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-Cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): Consideration of age greater than 70 years in an elderly prognostic index (E-1PI). Br Haematol 2010;151:143-151.
-
(2010)
Br Haematol
, vol.151
, pp. 143-151
-
-
Advani, R.H.1
Chen, H.2
Habermann, T.M.3
|